Free shipping on all orders over $ 500


Cat. No. M6085
GSK-1014802 Structure

CNV1014802; CNV-1014802; Raxatrigine

Size Price Availability Quantity
5mg USD 200 In stock
10mg USD 350 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013.

Cell Experiment
Cell lines HEK cells
Preparation method Activity of CNV1014802 was assessed in HEK cells heterologously expressing NaV1.1–NaV1.8 using FLIPR membrane potential assays.
Concentrations 1 mM
Incubation time 5 minutes
Animal Experiment
Animal models adult male C57BL/6J mice
Formulation phosphate-buffered saline/10% DMSO
Dosages 30 mg/kg
Administration i.v.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 314.35
Formula C18H19FN2O2
CAS Number 934240-30-9
Purity 99.93%
Solubility 10 mM in DMSO
Storage at -20°C

Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain.
Deuis JR, et al. Toxins (Basel). 2016 Mar 17;8(3). pii: E78. PMID: 26999206.

Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.
Zakrzewska JM, et al. Trials. 2013 Nov 23;14:402. PMID: 24267010.

Related Sodium Channel Products

GNE-131 is a potent and selective inhibitor of human sodium channel NaV1.7, with an IC50 of 3 nM.


PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.

Eleclazine hydrochloride

Eleclazine HCl is a novel late Na+ current inhibitor, with IC50 value of 0.7 uM.


Levobupivacaine is a reversible neuronal sodium channel inhibitor.


PF-05089771 is a selective Nav1.7 channel blocker that interacts with the voltage-sensor domain (VSD) of domain IV.

Abmole Inhibitor Catalog 2017

Keywords: GSK-1014802, CNV1014802; CNV-1014802; Raxatrigine supplier, Sodium Channel, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.